VCN Biosciences:

Highly selective viruses specifically designed
to treat refractory tumors

VCN Biosciences:

The company developing the next generation
of oncolytic adenovirus
Our oncolytic adenoviruses are designed
to obtain clinical activity by systemic administration

VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.



VCN Biosciences to present data with VCN-01 in patients with pancreatic cancer at ESMO 2019.

September 3, 2019 –VCN Biosciences, a clinical–stage company with a pipeline of different oncolytic immuno-oncology products, will present clinical data obtainedwith its lead candidate VCN-01 in patients with pancreatic carcinoma at the upcoming annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September –1 October2019.

Read more ...
VCN Biosciences to present Two Investor Conferences in May 2019.

May 6, 2019 – VCN Biosciences, a clinical–stage company developing oncolytic immuno-oncology products today announced that Manel Cascallo, Chief Executive Officer, will present at the following upcoming investor conferences:

Read more ...
VCN Biosciences announces initiation of clinical studies of VCN-01 in cancer patients.

May 2014. VCN Biosciences has announced that it has initiated its two first clinical studies examining the use of VCN-01in patients with cancer.

Read more ...
VCN Biosciences announcesthat MINECO has granted funding forthe project Cure4RB to clinically develop its lead candidate VCN-01for the treatment of retinoblastoma.

February, 2016 -A consortium led by VCN Biosciencesreceives funding for Cure4RBproject (RTC-2015-4319-1)by Ministerio de Economía y Competitividad (MINECO)from Spanish Government, programRETOS DE COLABORACIÓN -2015.

Read more ...